Superworth

908 Devices profit margin MASS

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months
−57.0%
Operating margin, 12 months
−64.0%
Net margin on a year earlier
−22.6 pts
Peer median
12.3%

Over the twelve months to Jun 30, 2026, 908 Devices kept −57.0% of its revenue as net profit, with an operating margin of −64.0% and a gross margin of 52.2%.

Five years earlier its net margin was −99.5%.

The median for 4 diagnostics and research stocks of a similar size is 12.3%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY202534.7%−70.1%50.6%
FY2024n/an/a51.3%
FY2023−72.5%−85.1%50.4%
FY2022−71.6%−75.5%55.5%
FY2021−52.5%−52.3%55.0%
FY2020−47.7%−21.6%55.5%

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−57.0%−22.6 pts−64.0%
Q1 FY26−62.4%−28.5 pts−71.4%
Q4 FY2534.7%n/a−70.1%
Q3 FY25−7.8%n/an/a
Q2 FY25−34.4%+45.6 ptsn/a
Q1 FY25−33.9%+38.3 ptsn/a
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24−79.9%−2.5 pts−73.5%
Q1 FY24−72.2%+4.1 pts−77.6%
Q4 FY23−72.5%−0.8 pts−85.1%
Q3 FY23−81.6%−28.2 pts−91.3%

Against its peers

Companies in Medical - Diagnostics & Research nearest 908 Devices' size, closest first, today.

CompanyProfit margin
MASS908 Devices−57.0%
NRCNRC Health4.2%
ICCCImmucell2.6%
CDNACareDx24.2%
VCYTVeracyte20.4%
Peer median12.3%

Where 908 Devices ranks

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on 908 Devices

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.